FindTrial
Sign In

A study on the clinical pathology, molecular genetics, diagnosis, treatment, and prognosis of hydroa vacciniforme-like lymphoproliferative disorder

A study on the clinical pathology, molecular genetics, diagnosis, treatment, and prognosis of hydroa vacciniforme-like lymphoproliferative disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070876
Enrollment
Unknown
Registered
2023-04-25
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hydroa vacciniforme-like lymphoproliferative disorder

Interventions

hydroa vacciniforme-like lymphoproliferative disorder:None
Inflammatory diseases:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of HVLPD was confirmed according to the 2016 edition of the World Health Organization classification of hematopoietic and lymphoid tumors. 2. Patients with clinical pathological data and the ability to provide skin tissue for further research.

Exclusion criteria

Exclusion criteria: Individuals with severe mental or language disorders, or a history of drug, drug, or alcohol abuse.

Design outcomes

Primary

MeasureTime frame
None;—

Countries

China

Contacts

Public ContactLin Wang

West China Hospital, Sichuan University

lkzwl@126.com+86 18980601701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026